<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01050777</url>
  </required_header>
  <id_info>
    <org_study_id>86783</org_study_id>
    <nct_id>NCT01050777</nct_id>
  </id_info>
  <brief_title>Efficacy of Topical Liposomal Form of Drugs in Cutaneous Leishmaniasis</brief_title>
  <official_title>Pilot Study of Efficacy of Topical Nano-liposomal Meglumine Antimoniate (Glucantime) or Paromomycin in Combination With Systemic Glucantime for the Treatment of Anthroponotic Cutaneous Leishmaniasis (ACL) Caused by Leishmania Tropica</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mashhad University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Center for Research and Training in Skin Diseases and Leprosy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Leishmaniasis with diverse clinical manifestations is caused by different species of&#xD;
      Leishmania and is endemic in many countries. Although Cutaneous Leishmaniasis (CL) is a&#xD;
      self-healing disease, but it takes a long time to heal. Pentavalent antimonials are still the&#xD;
      first-line treatment of CL which needs multiple injections, are painful and as such not&#xD;
      tolerated by most of the patients, in addition available treatments are not always effective&#xD;
      and resistance is reported. Paromomycin sulfate (PM) reported to show anti-Leishmania&#xD;
      activity against both CL and visceral leishmaniasis (VL) since 1960s. Therapeutic strategy&#xD;
      with high efficacy is urgently needed especially for Anthroponotic Cutaneous Leishmaniasis&#xD;
      (ACL). Liposomes are lipid bilayer molecules which entrap water-soluble molecules in their&#xD;
      internal water compartment and water-insoluble ones into their lipid bilayers. Liposomes, in&#xD;
      proper formulations and sizes, deliver drugs to the skin based on the similarity of the&#xD;
      bilayers structure of lipid vesicles to that of natural membrane and target the macrophages&#xD;
      within dermis. Several lipid-based formulations have been developed to treat experimental&#xD;
      leishmaniasis. Recently different doses of liposomal formulation of PM and liposomal&#xD;
      formulation of Glucantime were prepared and showed high efficacy in vivo against L. major&#xD;
      infection in BALB/c mice.&#xD;
&#xD;
      In this study the efficacy of liposomal formulation of PM or liposomal formulation of&#xD;
      Glucantime in combination with systemic Glucantime in the treatment of ACL parasitologically&#xD;
      proven patients will be evaluated. The clinical trial will be carried out according to the&#xD;
      International approved GCP (Good Clinical Practice) guide lines.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete cure equal to Complete Re-epithelization of all lesions</measure>
    <time_frame>200 days</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cutaneous Leishmaniasis</condition>
  <arm_group>
    <arm_group_label>Liposomal Paromomycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liposomes containing 10% Paromomycin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liposomal meglumine antimoniate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liposomes containing meglumine antimonate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal meglumine antimoniate (Glucantime)</intervention_name>
    <description>Liposomes containing meglumine antimoniate</description>
    <arm_group_label>Liposomal meglumine antimoniate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal meglumine antimoniate</intervention_name>
    <description>Liposomal form of meglumine antimoniate</description>
    <arm_group_label>Liposomal Paromomycin</arm_group_label>
    <arm_group_label>Liposomal meglumine antimoniate</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Paromomycin</intervention_name>
    <description>Liposomal form of 10% Paromomycin</description>
    <arm_group_label>Liposomal Paromomycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female aged between 12 to 60 years.&#xD;
&#xD;
          -  Parasitologically proven CL due to L. tropica.&#xD;
&#xD;
          -  History of failure to at least one full course of systemic Glucantime.&#xD;
&#xD;
          -  In general good health based on history and physical examination.&#xD;
&#xD;
          -  Number of lesion at most 4.&#xD;
&#xD;
          -  Lesion size less than 3 cm.&#xD;
&#xD;
          -  Signed informed consent voluntarily and knowingly.&#xD;
&#xD;
               -  Guardian's signature for volunteer less than 18 years old.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women and those who are planning to be pregnant in next 60 days.&#xD;
&#xD;
          -  Use of other types of treatment for CL.&#xD;
&#xD;
          -  Involvement in any other drug or vaccine trial during the study period.&#xD;
&#xD;
          -  Known heart, kidney, liver diseases based on history and physical exam. Abnormal ECG.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masud Maleki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mashhad University of Medical Sciences, Mashhad, Iran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ali Khamesipour, MPH, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Research &amp; Training in Skin Diseases &amp; Leprosy, TUMS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mahmoud Reza Jaafari, Parm D, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mashhad University of Medical Sciences, Mashhad, Iran</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emam Reza Hospital</name>
      <address>
        <city>Mashhad</city>
        <state>Khorasan Razavi</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>January 13, 2010</study_first_submitted>
  <study_first_submitted_qc>January 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2010</study_first_posted>
  <last_update_submitted>June 19, 2012</last_update_submitted>
  <last_update_submitted_qc>June 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tehran University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Ali Khamesipour</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Cutaneous Leishmaniasis caused by l. tropica</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Cutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paromomycin</mesh_term>
    <mesh_term>Meglumine Antimoniate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

